A retrospective cohort study analyzed patients with multiple myeloma (MM) refractory to anti-CD38 monoclonal antibody therapy, involving 663 patients, with a focus on those with triple class refractory (TCR) disease.

Read More >https://multiplemyeloma.pocn.com/patient-management/study-reveals-poor-outcomes-for-post-anti-cd38-therapy/